Quantbot Technologies LP boosted its position in shares of MAXIMUS, Inc. (NYSE:MMS) by 56.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,051 shares of the health services provider’s stock after buying an additional 2,903 shares during the period. Quantbot Technologies LP’s holdings in MAXIMUS were worth $523,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. BlackRock Inc. increased its stake in MAXIMUS by 6.5% during the 2nd quarter. BlackRock Inc. now owns 7,298,102 shares of the health services provider’s stock worth $453,284,000 after buying an additional 445,353 shares in the last quarter. Victory Capital Management Inc. increased its stake in MAXIMUS by 7.8% during the 3rd quarter. Victory Capital Management Inc. now owns 3,960,599 shares of the health services provider’s stock worth $257,677,000 after buying an additional 286,792 shares in the last quarter. Van Berkom & Associates Inc. increased its stake in MAXIMUS by 2.3% during the 3rd quarter. Van Berkom & Associates Inc. now owns 1,406,804 shares of the health services provider’s stock worth $91,527,000 after buying an additional 31,403 shares in the last quarter. Northern Trust Corp increased its stake in MAXIMUS by 1.8% during the 2nd quarter. Northern Trust Corp now owns 1,123,555 shares of the health services provider’s stock worth $69,785,000 after buying an additional 20,408 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC grew its position in shares of MAXIMUS by 8.2% in the third quarter. Thompson Siegel & Walmsley LLC now owns 1,059,800 shares of the health services provider’s stock valued at $68,951,000 after purchasing an additional 80,099 shares in the last quarter. Institutional investors own 93.29% of the company’s stock.

A number of equities research analysts have recently issued reports on MMS shares. ValuEngine upgraded MAXIMUS from a “hold” rating to a “buy” rating in a research report on Friday, November 30th. Zacks Investment Research upgraded MAXIMUS from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research report on Friday, November 23rd. Finally, Canaccord Genuity upped their price target on MAXIMUS from $64.00 to $67.00 and gave the company a “hold” rating in a research report on Wednesday, October 10th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. MAXIMUS has a consensus rating of “Buy” and an average target price of $72.00.

In related news, Vice Chairman Richard A. Montoni sold 15,000 shares of the stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $65.81, for a total value of $987,150.00. Following the completion of the transaction, the insider now directly owns 493,476 shares in the company, valued at $32,475,655.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Russell A. Beliveau sold 1,000 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $63.86, for a total value of $63,860.00. The disclosure for this sale can be found here. Insiders sold 133,124 shares of company stock valued at $9,005,450 over the last 90 days. Company insiders own 3.10% of the company’s stock.

MMS stock opened at $69.86 on Friday. The company has a market capitalization of $4.51 billion, a PE ratio of 21.72, a P/E/G ratio of 1.92 and a beta of 1.03. MAXIMUS, Inc. has a 1 year low of $60.00 and a 1 year high of $72.71.

MAXIMUS (NYSE:MMS) last posted its quarterly earnings results on Tuesday, November 20th. The health services provider reported $0.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.72 by ($0.01). The company had revenue of $558.50 million during the quarter, compared to analysts’ expectations of $587.58 million. MAXIMUS had a net margin of 9.23% and a return on equity of 20.23%. MAXIMUS’s revenue for the quarter was down 10.0% on a year-over-year basis. During the same quarter last year, the company earned $0.81 earnings per share. As a group, sell-side analysts predict that MAXIMUS, Inc. will post 3.66 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, November 30th. Stockholders of record on Thursday, November 15th were given a $0.25 dividend. The ex-dividend date was Wednesday, November 14th. This is a positive change from MAXIMUS’s previous quarterly dividend of $0.05. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.43%. MAXIMUS’s dividend payout ratio is 29.41%.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/12/08/quantbot-technologies-lp-boosts-holdings-in-maximus-inc-mms.html.

MAXIMUS Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services programs in the United States, the United Kingdom, Australia, Canada, Singapore, and Saudi Arabia. The company's Health Services segment offers various BPS, appeals, and assessments, as well as related consulting services for state, provincial, and national government programs comprising Medicaid, Children's Health Insurance Program, the Affordable Care Act, Health Insurance British Columbia, the Health Assessment Advisory Service, and Preadmission Screening and Resident Reviews.

Recommended Story: How dollar cost averaging works

Institutional Ownership by Quarter for MAXIMUS (NYSE:MMS)

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.